The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10651 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin-based combination therapy

Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum

March 27, 2018 - 15:32 -- Open Access
Author(s): 
Maëlle Duffey, Cecilia P. Sanchez and Michael Lanzer
Reference: 
Malaria Journal 2018 17:121, 20 March 2018

The results obtained in this study are consistent with artemisinins and SC83288 having distinct modes of action and different mechanisms of resistance.

The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates

March 13, 2018 - 13:25 -- Open Access
Author(s): 
Mathieu Gendrot, Francis Tsombeng Foguim, Marie Gladys Robert, Rémy Amalvict, Joel Mosnier, Nicolas Benoit, Marylin Madamet and Bruno Pradines
Reference: 
Malaria Journal 2018 17:108, 12 March 2018

The present data confirmed the absence of the association between polymorphisms in the RING E3 ubiquitin-protein ligase gene and the ex vivo susceptibility to common anti-malarial drugs in African P. falciparum isolates.

Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015

February 21, 2018 - 17:12 -- Open Access
Author(s): 
Dragan Ljolje, Pedro Rafael Dimbu, Mateusz M. Plucinski, et al.
Reference: 
Malaria Journal 2018 17:84, 20 February 2018

The pretreatment parasites in patients participating in therapeutic efficacy studies in 2015 in Angola’s three sentinel sites showed genetic evidence of susceptibility to artemisinins, consistent with clinical outcome data showing greater than 99% day 3 clearance rates.

Village malaria worker performance key to the elimination of artemisinin-resistant malaria: a Western Cambodia health system assessment

May 24, 2016 - 16:26 -- Open Access
Author(s): 
Sara E. Canavati, Saranath Lawpoolsri, Maxine Anne Whittaker, et al.
Reference: 
Malaria Journal 2016 15:282, 20 May 2016

VMW/MMW job performance must be increased from 80 to 100 % in order to achieve elimination.

K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar

February 26, 2016 - 17:16 -- Open Access
Author(s): 
Aye A. Win, Mallika Imwong, Myat P. Kyaw, Charles J. Woodrow, Kesinee Chotivanich, Borimas Hanboonkunupakarn and Sasithon Pukrittayakamee
Reference: 
Malaria Journal 2016 15:110, 24 February 2016

The proportion of P. falciparum isolates with mutations in the propeller region of k13 indicates that artemisinin resistance extends across much of Myanmar.

Country: 

Simultaneous quantification of artesunate and mefloquine in fixed-dose combination tablets by multivariate calibration with middle infrared spectroscopy and partial least squares regression

February 26, 2016 - 17:14 -- Open Access
Tags: 
Author(s): 
Breno Maurício Marson, Raquel de Oliveira Vilhena, Camilla Regina de Souza Madeira, Flávia Lada Degaut Pontes, Mário Sérgio Piantavini and Roberto Pontarolo
Reference: 
Malaria Journal 2016 15:109, 24 February 2016

MIR-PLS was found to be suitable for the quality control of these drugs.

Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015)

February 26, 2016 - 17:12 -- Open Access
Tags: 
Author(s): 
WHO Malaria Policy Advisory Committee and Secretariat
Reference: 
Malaria Journal 2016 15:117, 24 February 2016

The Malaria Policy Advisory Committee (MPAC) to the World Health Organization held its eighth meeting in Geneva, Switzerland from 16 to 18 September 2015.

Plasmodium falciparum drug resistance in Angola

February 9, 2016 - 16:59 -- Open Access
Author(s): 
Cláudia Fançony, Miguel Brito and Jose Pedro Gil
Reference: 
Malaria Journal 2016 15:74, 9 February 2016

Facing chloroquine drug resistance, Angola promptly adopted artemisinin-based combination therapy as the first-line to treat malaria.

Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model

September 4, 2013 - 11:29 -- Open Access
Author(s): 
Dormoi J, Briolant S, Pascual A, Desgrouas C, Travaillé C, Pradines B
Reference: 
Malaria Journal 2013, 12:302 (30 August 2013)
MalariaWorld

The combination of DHA and AVA seems to be effective as a therapeutic scheme for improving mouse survival but less effective for cytokine modulation, which is associated with protection against CM.

Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries

April 23, 2013 - 07:15 -- Open Access
Tags: 
Author(s): 
Davis B, Ladner J, Sams K, Tekinturhan E, de Korte D, Saba J
Reference: 
Malaria Journal 2013, 12:135 (22 April 2013)
MalariaWorld

Results from this study indicate that the AMFm has not fully achieved its affordability and crowd-out objectives

Pages

Subscribe to RSS - artemisinin-based combination therapy